BTIG Gives a Hold Rating to Regeneron

By Ryan Adsit

In a report released yesterday, Dane Leone from BTIG assigned a Hold rating to Regeneron (NASDAQ: REGN). The company’s shares closed yesterday at $342.67, close to its 52-week low of $314.99.

According to TipRanks.com, Leone is a 5-star analyst with an average return of 15.7% and a 71.8% success rate. Leone covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Voyager Therapeutics Inc, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Regeneron is Moderate Buy and the average price target is $445.10, representing a 29.9% upside.

In a report issued on February 2, Jefferies also reiterated a Hold rating on the stock with a $421 price target.

The company has a one-year high of $543.55 and a one-year low of $314.99. Currently, Regeneron has an average volume of 905K.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of REGN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in inventing medicines for people with serious diseases. It includes Arcalyst, Dupixent, Eylea, Kevzara, and Praluent injections. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.